METHADONE HYDROBROMIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H27NO.BrH
Molecular Weight	390.357
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Br.CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=FSICAXDYXLRLRG-UHFFFAOYSA-N

InChI=1S/C21H27NO.BrH/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19;/h6-15,17H,5,16H2,1-4H3;1H

HIDE SMILES / InChI

Molecular Formula	BrH
Molecular Weight	80.912
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C21H27NO
Molecular Weight	309.4452
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021624s006lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/006134s040s041lbl.pdf | https://www.drugs.com/pro/diskets.html

Methadone, sold under the brand names Dolophine among others, is an synthetic opioid that is used as the hydrochloride to treat pain and as maintenance therapy or to help with detoxification in people with opioid dependence. Methadone hydrochloride is a mu-agonist; a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine. Some data also indicate that methadone acts as an antagonist at the NMDA-receptor. The contribution of NMDA receptor antagonism to methadone’s efficacy is unknown. Most common adverse reactions are: lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. Avoid use mixed agonist/antagonist and partial agonist opioid analgesics with DOLOPHINE because they may reduce analgesic effect of DOLOPHINE or precipitate withdrawal symptoms.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mu opioid receptor 221 Target ID: CHEMBL233 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/006134s040s041lbl.pdf	Agonist 2678		3.51 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 614 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/006134s040s041lbl.pdf	Palliative		Approved 8429	DOLOPHINE HYDROCHLORIDE Approved Use For the treatment of moderate to severe pain not responsive to non-narcotic analgesics. For detoxification treatment of opioid addiction (heroin or other morphine-like drugs). For maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. Note – Outpatient maintenance and outpatient detoxification treatment may be provided only by Opioid Treatment Programs (OTPs) certified by the Federal Substance Abuse and Mental Health Services Administration (SAMHSA) and registered by the Drug Enforcement Administration (DEA). This does not preclude the maintenance treatment of a patient with concurrent opioid addiction who is hospitalized for conditions other than opioid addiction and who requires temporary maintenance during the critical period of his/her stay, or of a patient whose enrollment has been verified in a program which has been certified for maintenance treatment with methadone. Launch Date 1947
Detoxification & maintenance treatment of opioid addiction 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/006134s040s041lbl.pdf	Palliative		Approved 8429	DOLOPHINE HYDROCHLORIDE Approved Use For the treatment of moderate to severe pain not responsive to non-narcotic analgesics. For detoxification treatment of opioid addiction (heroin or other morphine-like drugs). For maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. Note – Outpatient maintenance and outpatient detoxification treatment may be provided only by Opioid Treatment Programs (OTPs) certified by the Federal Substance Abuse and Mental Health Services Administration (SAMHSA) and registered by the Drug Enforcement Administration (DEA). This does not preclude the maintenance treatment of a patient with concurrent opioid addiction who is hospitalized for conditions other than opioid addiction and who requires temporary maintenance during the critical period of his/her stay, or of a patient whose enrollment has been verified in a program which has been certified for maintenance treatment with methadone. Launch Date 1947

C_max

Value	Dose	Analyte	Population
548 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8641323/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	METHADONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
494 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15151520/	70 mg 1 times / day steady-state, oral dose: 70 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	METHADONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
40.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22621465/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	METHADONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
54 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8641323/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
8.54 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8641323/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	METHADONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
8.27 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15151520/	70 mg 1 times / day steady-state, oral dose: 70 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	METHADONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1073 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22621465/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	METHADONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.61 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8641323/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
31.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8641323/	60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	METHADONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15151520/	70 mg 1 times / day steady-state, oral dose: 70 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	METHADONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
39.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22621465/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	METHADONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
10 mg 3 times / day multiple, intravenous (starting) Recommended Dose: 10 mg, 3 times / day Route: intravenous Route: multiple Dose: 10 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf	pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf	Other AEs: Withdrawal syndrome neonatal... Other AEs: Withdrawal syndrome neonatal Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
10 mg 3 times / day multiple, intravenous (starting) Recommended Dose: 10 mg, 3 times / day Route: intravenous Route: multiple Dose: 10 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf	Other AEs: Respiratory depression, Addiction... Other AEs: Respiratory depression (grade 5) Addiction QT interval prolonged (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
20 mg single, oral (starting) Recommended Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf	Other AEs: Respiratory depression, QT interval prolonged... Other AEs: Respiratory depression (grade 5) QT interval prolonged Arrhythmia (serious) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf

AEs

AE	Significance	Dose	Population
Withdrawal syndrome neonatal		10 mg 3 times / day multiple, intravenous (starting) Recommended Dose: 10 mg, 3 times / day Route: intravenous Route: multiple Dose: 10 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf	pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
Addiction		10 mg 3 times / day multiple, intravenous (starting) Recommended Dose: 10 mg, 3 times / day Route: intravenous Route: multiple Dose: 10 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
QT interval prolonged	grade 5	10 mg 3 times / day multiple, intravenous (starting) Recommended Dose: 10 mg, 3 times / day Route: intravenous Route: multiple Dose: 10 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
Respiratory depression	grade 5	10 mg 3 times / day multiple, intravenous (starting) Recommended Dose: 10 mg, 3 times / day Route: intravenous Route: multiple Dose: 10 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf
QT interval prolonged		20 mg single, oral (starting) Recommended Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf
Respiratory depression	grade 5	20 mg single, oral (starting) Recommended Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf
Arrhythmia	serious	20 mg single, oral (starting) Recommended Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	substrate 1037	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2E1 882 CYP1A 72 CYP2B 15 CYP2C 19 UGT2B7 146 UGT2B4 19	CYP2B6 664 CYP2C19 991 P-gp 1537 OATP1A2 62 OATP1B1 406 OATP1B3 350 OATP2B1 104 OCT1 327 OCT2 355 OCT3 80 BCRP 561

Drug as perpetrator

Target	Modality	Activity
UGT2B4 19	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/20484152/ Page: 8.0	major [Inhibition 0.6 uM]
CYP1A 121	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9020195/	no
CYP2B 40	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9020195/	no
CYP2C 34	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9020195/	no
CYP2E1 970	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9020195/	no
UGT2B7 157	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/20484152/ Page: 8.0	unlikely
CYP3A4 1925	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014462/	yes [Ki 100 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1381486/	yes [Ki 2.5 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
BCRP 561	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339814/	no
OATP1A2 62	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339814/	no
OATP1B1 406	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339814/	no
OATP1B3 350	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339814/	no
OATP2B1 104	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339814/	no
OCT1 327	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339814/	no
OCT2 355	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339814/	no
OCT3 80	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339814/	no
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/006134s049lbl.pdf#page=29; https://pubmed.ncbi.nlm.nih.gov/22035341/ Page: 29.0	yes
CYP2B6 664	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/006134s049lbl.pdf#page=29; https://pubmed.ncbi.nlm.nih.gov/22035341/ Page: 29.0	yes	yes (co-administration study) Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/006134s049lbl.pdf#page=29; https://pubmed.ncbi.nlm.nih.gov/22035341/ Page: 29.0
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/006134s049lbl.pdf#page=29; https://pubmed.ncbi.nlm.nih.gov/22035341/ Page: 29.0	yes	yes (co-administration study) Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/006134s049lbl.pdf#page=29; https://pubmed.ncbi.nlm.nih.gov/22035341/ Page: 29.0
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/006134s049lbl.pdf#page=29; https://pubmed.ncbi.nlm.nih.gov/22035341/ Page: 29.0	yes	yes (co-administration study) Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/006134s049lbl.pdf#page=29; https://pubmed.ncbi.nlm.nih.gov/22035341/ Page: 29.0
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/006134s049lbl.pdf#page=29; https://pubmed.ncbi.nlm.nih.gov/22035341/ Page: 29.0	yes	yes (co-administration study) Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/006134s049lbl.pdf#page=29; https://pubmed.ncbi.nlm.nih.gov/22035341/ Page: 29.0
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/006134s049lbl.pdf#page=29; https://pubmed.ncbi.nlm.nih.gov/22035341/ Page: 29.0	yes	yes (co-administration study) Comment: CYP450 inducers: concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms; phenytoin administration resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. CYP450 inhibitors: Repeat dose administration of oral voriconazole increased the peak plasma concentration (Cmax) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose. The Cmax and AUC of (S)-methadone increased by 65% and 103%, respectively Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/006134s049lbl.pdf#page=29; https://pubmed.ncbi.nlm.nih.gov/22035341/ Page: 29.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/17329992/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:6807	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6807
eMolecules	979329	https://www.emolecules.com/cgi-bin/more?vid=979329

PubMed

Title	Date	PubMed
Reversible spastic paraparesis induced by high-dose intravenous methadone.	2001 Feb	14622789
Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study.	2003 Nov	14616189
QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone.	2003 Oct 15	14556883
[Torsade de pointes: a severe and unknown adverse effect in a patient taking methadone].	2003 Oct 8	14587370
[Development of transmural myocardial infarction in young persons with intact coronary arteries during methadone use for the treatment of heroine addiction].	2004	15477802
Relationship between prescribing and risk of opiate overdose among drug users in and out of maintenance treatment.	2004	14665804
Cost effectiveness of disulfiram: treating cocaine use in methadone-maintained patients.	2004 Apr	15063917
QT interval prolongation in patients on methadone with concomitant drugs.	2004 Aug	15232338
Methadone metabolism by human placenta.	2004 Aug 1	15242824
[Life-threatening, recurrent arrhythmia in patients on high-dose methadone treatment: torsade de pointes].	2004 Aug 30	15387312
Obsessive-compulsive symptoms precipitated by methadone tapering.	2004 Dec	15538140
Methadone-induced torsade de pointes in a patient with normal baseline QT interval.	2004 Jul-Aug	15471174
Directly observed therapy for the management of HIV-infected patients in a methadone program.	2004 Jun 1	15156430
The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.	2004 May	15089813
Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials.	2004 May	15039761
[Routine ECG in methadone-assisted rehabilitation is wrong prioritization].	2004 Nov 18	15550974
Oral methadone for cancer pain: no indication of Q-T interval prolongation or torsades de pointes.	2004 Oct	15471646
Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma.	2004 Oct	15454842
[Preclinical management of accidental methadone intoxication of a 4-year-old girl. Antagonist or intubation?].	2004 Oct	15278196
[Long QT and torsade de pointes in a patient with acquired human immunodeficiency virus infection in multitherapy with drugs affecting cytochrome P450].	2004 Sep	15568612
Epidural clonidine, bupivacaine and methadone as the sole analgesic agent after thoracotomy for lung resection.	2004 Sep	15310347
Methadone maintenance and male sexual dysfunction.	2005	15784526
Cocaine-related torsade de pointes in a methadone maintenance patient.	2005	15774410
Adipocyte-derived hormones in heroin addicts: the influence of methadone maintenance treatment.	2005	15717844
QTc interval prolongation in patients on long-term methadone maintenance therapy.	2005	15608471
Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes.	2005 Apr	15977920
Torsades de pointes with methadone.	2005 Apr	15875343
Measurement of QTc in patients receiving chronic methadone therapy.	2005 Apr	15857742
Methadone-related Torsades de Pointes in a sickle cell patient treated for chronic pain.	2005 Apr	15795907
[Methadone-induced heart arrhythmia].	2005 Aug 11	16100543
Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver.	2005 Dec 12	15964714
Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.	2005 Feb	15677600
Methadone-induced bradycardia.	2005 Jul	15961013
Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers.	2005 Jun 1	15893159
Dextromethorphan-induced delirium and possible methadone interaction.	2005 Mar	16089243
[Methadone and sleep apnea syndrome].	2005 Mar	15830825
Caution with nalbuphine in patients on long-term opioids.	2005 Mar	15810761
Methadone-induced Torsade de pointes tachycardias.	2005 May 14	15986265
QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.	2005 Nov	15918160
[Torsades de pointes during methadone treatment].	2005 Oct	16238992
Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers.	2005 Oct	16185211
QT prolongation and syncope with methadone, doxepin, and a beta-blocker.	2005 Oct	16144878
Central sleep apnea in stable methadone maintenance treatment patients.	2005 Sep	16162728
Methadone treatment of chronic non-malignant pain and opioid dependence--a long-term follow-up.	2006 Apr	15972261
Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients.	2006 Apr 28	16154297
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence.	2006 Jan	16496034
Bradycardia during methadone therapy in an infant.	2006 Jan	16395081
A randomized controlled trial of interim methadone maintenance.	2006 Jan	16389204
Frequency of high-risk use of QT-prolonging medications.	2006 Jun	16178046
Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence.	2006 May	16085366

Patents

Sample Use Guides

In Vivo Use Guide

Chronic pain: oral initial dose - 2.5 mg every 8 to 12 hours; Intravenous initial dose: 2.5 mg to 10 mg every 8 to 12 hours Opiate withdrawal: Initial dose - 20 to 30 mg orally; an additional 5 to 10 mg may be given orally after 2 to 4 hours if withdrawal symptoms have not been suppressed or if symptoms reappear. -Maximum initial dose: 30 mg -Maximum day 1 dose: 40 mg

Route of Administration: Other

In Vitro Use Guide

In the presence of 1 uM methadone, the maximum 86Rb+ efflux stimulated by nicotine (Emax) was markedly reduced, but the EC50 for nicotine was altered only slightly, if at all.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:15:58 GMT 2023` Edited by `admin` on `Sat Dec 16 11:15:58 GMT 2023`
Record UNII	8CJ41S2M6U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

METHADONE HYDROBROMIDE

Common Name

English

3-HEPTANONE, 6-(DIMETHYLAMINO)-4,4-DIPHENYL-, HYDROBROMIDE

Systematic Name

English

DL-METHADONE HYDROBROMIDE

Common Name

English

Code System Code Type Description

PUBCHEM

135036